BioCardia Q1 EPS $(0.09) Up From $(0.17) YoY, Sales $55.00K Down From $64.00K YoY
Portfolio Pulse from Benzinga Newsdesk
BioCardia (NASDAQ:BCDA) reported a Q1 EPS of $(0.09), improving from $(0.17) YoY, but saw a decrease in sales to $55.00K from $64.00K YoY.
May 14, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioCardia reported improved quarterly losses but decreased sales year-over-year.
The improvement in EPS indicates a positive direction in reducing losses, which could be seen favorably by investors. However, the decrease in sales year-over-year might raise concerns about the company's growth trajectory and could potentially offset the positive impact of the improved EPS. The net effect on the stock price in the short term is likely to be neutral as investors weigh the improved loss per share against the decrease in sales.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100